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Microglia are tissue-resident macrophages playing essen-
tial roles in central nervous system (CNS) development and 
homeostasis [14, 17]. The importance of microglia for brain 
health in humans has been highlighted by the definition of 
Mendelian disorders associated with dysfunction of micro-
glia-related proteins. These so-called microgliopathies [20] 
comprise a diverse set of neurological phenotypes including 
disease due to mutations in CSF1R [5, 8, 13], DAP12 and 
TYROBP/TREM2 [4, 7], USP18 [3, 11, 16, 18], and IRF8 
[2, 6]. Here, we describe a novel early onset lethal encepha-
lopathy due to mutations in the microglial-associated protein 
NRROS.
We ascertained three patients demonstrating a stereotyped 
clinical and neuroradiological phenotype (Supplementary 
material). Patients 1 (P1) and P2, both females, were the 
first and third children of non-consanguineous parents of 
Maori descent (family F1442), whilst P3 (family F2382), 
a male, was the first child of first cousin south Asian par-
ents (Supplementary Figure 1). All three children were born 
after a normal pregnancy and delivery, and early develop-
ment was unremarkable. However, in the second year of 
life, they experienced the onset of refractory seizures and 
neurodegeneration, leading to death between the ages of 
27 and 36 months. Metabolic testing, including for mito-
chondrial dysfunction, was non-contributory. Neuroimaging 
initially demonstrated fine calcification at the depths of the 
cerebral gyri, with normal white matter (Fig. 1). As disease 
progressed, repeat imaging revealed increased calcification, 
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severe generalized atrophy with ventricular dilatation, and 
diffuse signal changes in cerebral and cerebellar white 
matter.
Exome sequencing identified homozygous NRROS 
variants in the affected children from both families: a 
c.1777C > T/p.(Gln593*) and a c.1257del/p.(Gly420Alaf-
sTer14) in F1442 and F2382, respectively. Cellular material 
was not available from any of the patients. However, both of 
these variants are predicted to result in a truncated protein, 
and both are very rare, with the p.(Gln593*) not previously 
recorded, and the p.(Gly420AlafsTer14) reported on only 1 
of 251,438 alleles on gnomAD.
Detailed pathological examination was undertaken on P3, 
demonstrating abnormalities confined to the CNS. Gross 
examination indicated a significant cerebral atrophy (Sup-
plementary Figure 2). Histologically, there was both grey 
and white matter pathology throughout the cerebrum, cer-
ebellum, and brainstem. Focal calcification was noted in the 
neuropil. There was widespread neuronal loss with reactive 
gliosis throughout the grey matter (Supplementary Figure 3). 
The most striking pathological finding was the accumula-
tion of foamy macrophages, predominantly in a perivascular 
distribution, throughout the white matter, extending from 
frontal to occipital white matter (Fig. 2a–c), and through cer-
ebellar white matter and descending corticospinal pathways 
in the basis pontis. These foamy cells immunoreacted with 
CD68, MHC Class II (CR3/43), and p22phox (Fig. 2c–f), 
but did not immunoreact with CD163, Iba1, NRROS, CD3, 
P2Y12, or TMEM119 (Supplementary Figure 3). There was 
reduced myelin basic protein (MBP) expression in the white 
matter (Fig. 2g) compared to age-matched controls, although 
there was preservation of U fibers. Occasional axonal sphe-
roids were noted, albeit this was not a prominent feature 
(Supplementary Figure 3).
We assessed the cellular expression of NRROS, and the 
mouse homolog Nrros (Lrrc33), in human and mouse brain 
Fig. 1  Neuroimaging of patients from F1442 and F2382. CT images 
of patient 1 (P1) aged 9 months (a), patient 2 (P2) aged 17 months 
(f), and patient 3 (P3) aged 14  months (j) demonstrate widespread 
spot and linear calcification in the deep and sub-cortical white mat-
ter. T2-weighted axial MR images of P1 aged 9  months (b, d) and 
27 months (c, e), P2 aged 17 months (g, h, i), and P3 aged 14 months 
(k, m) and 27 months (l, n). Initial imaging shows mild cerebral vol-
ume loss with relatively good myelination. Follow-up shows rapidly 
progressive cortical and sub-cortical atrophy in P1 and P3. There is 
diffuse high signal in the white matter in P3 (l, n), but not P1
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respectively, by mining curated transcriptomic data sets 
(Supplementary Figure 4). In fresh post-mortem human 
cortical microglia and brain samples, NRROS was highly 
expressed in isolated microglia, although less abundantly 
than established microglial signature genes. The expression 
of NRROS was enriched > 50-fold in microglia compared 
to whole brain, indicating that microglia are the major cell 
type expressing NRROS in human brain parenchyma. A sim-
ilar pattern of highly enriched expression of Lrrc33/Nrros 
was observed in  CD11b+ microglia/macrophages in mouse 
brain relative to brain extracts, and in microglia versus other 
parenchymal cell types. Comparison of parenchymal micro-
glia with CNS perivascular macrophages (PVMs) showed 
significantly greater expression in the latter.
The clinical features observed in our patients recapitulate 
those in mice with Nrros/Lrrc33 deficiency. Nrros−/−mice 
exhibited progressive neurological decline, including 
motor defects and abnormal locomotor activity, from age 
2–3 months and death by 6 months of age [15, 21]. Neuro-
pathology in these mouse models includes neuronal loss, 
demyelination, axonal pathology, astrogliosis, and the 
increased presence of foamy macrophages, all of which 
were seen in our case. Of note, there was no indication of 
immune-mediated inflammation in our case or either of 
these mouse models.
NRROS is a leucine-rich repeat containing transmem-
brane protein localized to the endoplasmic reticulum, 
and preferentially expressed in myeloid cells. Reported 
functions include the regulation of reactive oxygen species 
(ROS) production through control of NOX2 stability [12], 
responsiveness of Toll-like receptor signaling [19], and pro-
cessing/activation of transforming growth factor (TGF)-β 
via physical interactions with the latent complex [10, 15]. 
NRROS expression is restricted to microglia within the 
CNS parenchymal compartment in humans and mice. The 
present case showed disruption to the distribution, density, 
and cell morphology of IBA1 cells alongside loss of P2Y12 
staining and weak TMEM119 immunoreactivity, indica-
tive of marked parenchymal microglial abnormalities. Both 
Nrros−/− mouse studies observed a loss of homeostatic gene 
expression profile which included suppression of P2ry12 
and Tmem119 expression, and a shift towards a phenotype 
resembling PVMs [15, 21]. Although Nrros is expressed 
in peripheral mononuclear cells, a series of crosses and 
bone marrow transplant experiments showed a negligible 
contribution of peripheral macrophages to the onset of the 
Nrros−/− phenotype [21]. Of note, selective deletion of 
Nrros in microglia during pregnancy indicated a cell-intrin-
sic role for NRROS. In contrast, Nrros deletion induced in 
3-week-old mice did not cause neuropathological changes 
or neurological abnormalities [21], implying that NRROS 
is important during microglial establishment at embryonic/
postnatal stages, but may be dispensable for maintenance 
of adult microglia. Functions of NRROS proposed above, 
notably in ROS and TGFβ regulation, may be important in 
disease pathogenesis. p22phox was markedly up-regulated in 
Fig. 2  Post-mortem histological examination of patient 3 (P3). a 
Low-power view of occipital white matter with accumulation of 
foamy cells, predominantly in a perivascular location (black arrows 
for highlighted examples) (H&E: × 100); b the perivascular distribu-
tion being highlighted at a higher power (H&E × 200). Granular mate-
rial is present in the cytoplasm of these foamy cells (c H&E × 600). 
The white matter foamy cells were predominantly, but not exclu-
sively, limited to a perivascular distribution and expressed CD68 
(d CD68 IHC × 200), HLA DR/DP/DQ (e CR3/43 IHC × 100), and 
p22PHOX (f p22phox IHC × 200). There was partial preservation 
of myelin in sub-cortical U fibers, but loss of myelin when assessed 
by myelin basic protein expression in deeper white matter (g myelin 
basic protein IHC × 100)
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PVMs in our case, suggesting that an absence of functional 
NRROS may result in increased p22phox-NOX2 binding, 
with the potential for increased superoxide radical forma-
tion. However, a cross of Nrros−/− and Cybb−/− (encoding 
NOX2) mice did not rescue the Nrros−/− phenotype [21]. 
Mice with CNS or microglial-restricted disruption during 
development of other key nodes in the TGFβ activation/
signaling pathway, including deletion of αVβ8 integrin or 
TGFBR2 [1], develop highly similar pathological, micro-
glial, and neurological abnormalities to Nrros−/− mice. 
Moreover, human TGFβ1 loss-of-function mutations caus-
ing early onset leukoencephalopathy were described recently 
[9].
Taken together with the mouse data, our findings indi-
cate that NRROS is indispensable in controlling the early 
development of a homeostatic microglial population and/or 
its ongoing preservation in the postnatal brain, thereby sug-
gesting a loss of NRROS function as a novel microgliopathy 
in humans.
Acknowledgements YJC acknowledges a state subsidy managed by 
the National Research Agency (France) under the ‘Investments for 
the Future’ program bearing the reference ANR-10-IAHU-01 and the 
MSDAvenir fund (DEVO-DECODE Project). YJC and CS acknowl-
edge the RS MacDonald Seed-corn Fund. The DDD study presents 
independent research commissioned by the Health Innovation Chal-
lenge Fund (Grant number HICF-1009-003), a parallel funding part-
nership between the Wellcome Trust and the Department of Health, 
and the Wellcome Trust Sanger Institute (Grant number WT098051). 
BWM acknowledges funding from the UK Dementia Research Institute 
and Medical Research Council (MR/L003384/1, MR/R001316/1). YJC 
thanks David Fitzpatrick for advice.
Open Access This article is licensed under a Creative Commons Attri-
bution 4.0 International License, which permits use, sharing, adapta-
tion, distribution and reproduction in any medium or format, as long 
as you give appropriate credit to the original author(s) and the source, 
provide a link to the Creative Commons licence, and indicate if changes 
were made. The images or other third party material in this article are 
included in the article’s Creative Commons licence, unless indicated 
otherwise in a credit line to the material. If material is not included in 
the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will 
need to obtain permission directly from the copyright holder. To view a 
copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.
References
 1. Arnold TD, Lizama CO, Cautivo KM, Santander N, Lin L, Qiu H 
et al (2019) Impaired αVβ8 and TGFβ signaling lead to microglial 
dysmaturation and neuromotor dysfunction. J Exp Med 216:900–
915. https ://doi.org/10.1084/jem.20181 290
 2. Bigley V, Maisuria S, Cytlak U, Jardine L, Care MA, Green K et al 
(2018) Biallelic interferon regulatory factor 8 mutation: a complex 
immunodeficiency syndrome with dendritic cell deficiency, mono-
cytopenia, and immune dysregulation. J Allergy Clin Immunol 
141:2234–2248. https ://doi.org/10.1016/j.jaci.2017.08.044
 3. Goldmann T, Zeller N, Raasch J, Kierdorf K, Frenzel K, Ketscher 
L et al (2015) USP18 lack in microglia causes destructive inter-
feronopathy of the mouse brain. EMBO J 34:1612–1629. https ://
doi.org/10.15252 /embj.20149 0791
 4. Guerreiro RJ, Lohmann E, Bras JM, Gibbs JR, Rohrer JD, Gurun-
lian N et al (2013) Using exome sequencing to reveal mutations in 
TREM2 presenting as a frontotemporal dementia-like syndrome 
without bone involvement. JAMA Neurol 70:78–84. https ://doi.
org/10.1001/jaman eurol .2013.579
 5. Guo L, Bertola DR, Takanohashi A, Saito A, Segawa Y, Yokota 
T et al (2019) Bi-allelic CSF1R mutations cause skeletal dys-
plasia of dysosteosclerosis-pyle disease spectrum and degenera-
tive encephalopathy with brain malformation. Am J Hum Genet 
104:925–935. https ://doi.org/10.1016/j.ajhg.2019.03.004
 6. Hambleton S, Salem S, Bustamante J, Bigley V, Boisson-Dupuis 
S, Azevedo J et al (2011) IRF8 mutations and human dendritic-
cell immunodeficiency. N Engl J Med 365:127–138. https ://doi.
org/10.1056/NEJMo a1100 066
 7. Konishi H, Kiyama H (2018) Microglial TREM2/DAP12 signal-
ing: a double-edged sword in neural diseases. Front Cell Neurosci 
12:206. https ://doi.org/10.3389/fncel .2018.00206 
 8. Konno T, Kasanuki K, Ikeuchi T, Dickson DW, Wszolek ZK 
(2018) CSF1R-related leukoencephalopathy: a major player in 
primary microgliopathies. Neurology 91:1092–1104. https ://doi.
org/10.1212/WNL.00000 00000 00664 2
 9. Kotlarz D, Marquardt B, Barøy T, Lee WS, Konnikova L, Hol-
lizeck S et al (2018) Human TGF-β1 deficiency causes severe 
inflammatory bowel disease and encephalopathy. Nat Genet 
50:344–348. https ://doi.org/10.1038/s4158 8-018-0063-6
 10. Ma W, Qin Y, Chapuy B, Lu C (2019) LRRC33 is a novel bind-
ing and potential regulating protein of TGF-β1 function in human 
acute myeloid leukemia cells. PLoS One 14:e0213482. https ://doi.
org/10.1371/journ al.pone.02134 82
 11. Meuwissen ME, Schot R, Buta S, Oudesluijs G, Tinschert S, Speer 
SD et al (2016) Human USP18 deficiency underlies type 1 inter-
feronopathy leading to severe pseudo-TORCH syndrome. J Exp 
Med 213:1163–1174. https ://doi.org/10.1084/jem.20151 529
 12. Noubade R, Wong K, Ota N, Rutz S, Eidenschenk C, Valdez PA 
et al (2014) NRROS negatively regulates reactive oxygen species 
during host defence and autoimmunity. Nature 509:235–239. https 
://doi.org/10.1038/natur e1315 2
 13. Oosterhof N, Chang IJ, Karimiani EG, Kuil LE, Jensen DM, 
Daza R et al (2019) Homozygous mutations in CSF1R cause a 
pediatric-onset leukoencephalopathy and can result in congenital 
absence of microglia. Am J Hum Genet 104:936–947. https ://doi.
org/10.1016/j.ajhg.2019.03.010
 14. Prinz M, Priller J (2014) Microglia and brain macrophages in the 
molecular age: from origin to neuropsychiatric disease. Nat Rev 
Neurosci 15:300–312. https ://doi.org/10.1038/nrn37 22
 15. Qin Y, Garrison BS, Ma W, Wang R, Jiang A, Li J et al (2018) A 
milieu molecule for TGF-β required for microglia function in the 
nervous system. Cell 174:156–171.e16. https ://doi.org/10.1016/j.
cell.2018.05.027
 16. Rodero MP, Crow YJ (2016) Type I interferon-mediated mono-
genic autoinflammation: the type I interferonopathies, a concep-
tual overview. J Exp Med 213:2527–2538. https ://doi.org/10.1084/
jem.20161 596
 17. Salter MW, Stevens B (2017) Microglia emerge as central players 
in brain disease. Nat Med 23:1018–1027. https ://doi.org/10.1038/
nm.4397
 18. Schwabenland M, Mossad O, Peres AG, Kessler F, Maron FJM, 
Harsan LA et al (2019) Loss of USP18 in microglia induces white 
matter pathology. Acta Neuropathol Commun 7:106. https ://doi.
org/10.1186/s4047 8-019-0757-8
 19. Su X, Mei S, Liang X, Wang S, Liu J, Zhang Y et al (2014) Epi-
genetically modulated LRRC33 acts as a negative physiological 
Acta Neuropathologica 
1 3
regulator for multiple Toll-like receptors. J Leukoc Biol 96:17–26. 
https ://doi.org/10.1189/jlb.08134 57
 20. van der Knaap MS, Bugiani M (2017) Leukodystrophies: a pro-
posed classification system based on pathological changes and 
pathogenetic mechanisms. Acta neuropathol 134:351–382. https 
://doi.org/10.1007/s0040 1-017-1739-1
 21. Wong K, Noubade R, Manzanillo P, Ota N, Foreman O, Hack-
ney JA et al (2017) Mice deficient in NRROS show abnormal 
microglial development and neurological disorders. Nat Immunol 
18:633–641. https ://doi.org/10.1038/ni.3743
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
